Truly human antibody therapeutics.
Humans mount lasting antibody responses to infectious diseases and cancer. Abterra Bio uses next-generation sequencing, mass spectrometry, and machine learning to comprehensively map the antibody response, and rapidly identify better therapeutic antibodies. We’ve built an interdisciplinary team of data scientists and biologists to re-imagine how antibody therapeutics are developed.
Abterra Bio technology is built on decades of experience in antibody sequencing and analysis. Click on the services below to see how we can help you!
REPTOR™
Next-Gen Sequencing Hybridoma
REPTOR™
Next-Gen Sequencing Bulk B Cells
REPTOR™
Next-Gen Sequencing Hit Expansion
REPTOR™
Next-Gen Sequencing Display Library
ALICANTO®
Rabbit Monoclonal Antibody Discovery
ALICANTO®
Single Domain (VHH) Antibody Discovery
ALICANTO®
Human Antibody Discovery
VALENS™
Protein Sequence Confirmation
VALENS™
Antibody Protein Sequencing
Our partners’ success means everything to us
I have had great experiences using Abterra Bio’s Reptor platform. The data generated was highly valuable, and the team provided quick and open communication throughout the whole process.
I would strongly recommend the services, Valens and Reptor, from Abterra Bio. Not only were the individuals extremely helpful throughout the development of my project, but they were always available to answer any questions I had throughout the project. Best of all, Abterra provided high-quality sequences with a rapid turnover which allowed my lab to continue our research with little delay.
Latest News
PEGS Boston Summit 2021 Presentation
Abstract: Next-generation sequencing of antibody repertoires has provided new insights into natural immune responses. The correlation between the B-cell receptor repertoire and the serological antibody repertoire has only been analyzed in a small number of studies. ...
Abterra Bio Seattle Angel Conference Winner
We’re excited to announce that Abterra Bio has been chosen as the Winner of the 19th Seattle Angel Conference and the Audience Favorite Award. This year, there were 81 start-up companies from all over the US that had applied. The selection process took around 2-3...
Digital Proteomics is Abterra Biosciences
We're excited to announce that Digital Proteomics is now Abterra Biosciences. Our vision for the business has evolved and it's time to realign our name with our capabilities; we have developed core technologies that are driving our partners' antibody discovery...
We are a CONNECT Cool Company 2021!
We’re excited to announce that Abterra Biosciences has been selected as "A Cool Company" for the second year in a row by CONNECT. CONNECT, a premier innovation company accelerator in San Diego that creates and scales great companies in the technology and life sciences...
Scientific Updates
Why Sequence My Antibody Protein?
Over the past decade of sequencing thousands of antibodies, we've discovered the top reasons to sequence your antibody protein.Top reasons to sequence my antibody 1. To protect my intellectual property through patents for regulatory application and antibody...
Case Study: Alicanto Discovers High Affinity Rabbit Antibodies to Detect Neurofibromin
Researchers at Infixion Bioscience are on a mission to develop new therapeutics for the “orphan disease” neurofibromatosis type 1, which is diagnosed at a rate 1 in 3000 live births, impacting millions across the globe. Neurofibromatosis type 1 is a genetic disorder...
Customer Spotlight: Dr. Matthew Burchill
Valens™ Rescues Antibody for Liver Disease ResearchDr. Matthew Burchill explains how Abterra Bio's technology, Valens rescued his antibody and enabled him to continue his research in chronic liver disease. "The sequencing provided is instrumental to our work as the...
Multi-Species Antibody Repertoire Comparison
A decade ago, in vivo antibody discovery relied heavily on wild-type mice. Today, it’s not uncommon to generate antibodies using a petting zoo of animals including chicken, goat, rabbit, llamas, alpacas, and humanized rodents. The immune responses of these animals...
Every day, we strive to help our partners and collaborators push the boundaries of their science.
